Rådholm K, et al. - In view of the fact that inhibitors of sodium glucose cotransporter 2 (SGLT2) prevent cardiovascular complications in type 2 diabetes, researchers investigated whether they have similar effects in both men and women. Participants in the study were patients with type 2 diabetes enrolled in the EMPA-REG OUTCOME, CANVAS Program, DECLARE TIMI-58 and CREDENCE trials. Findings revealed that there were no gender differences in the risk ratios, SGLT2 vs control, for vascular efficacy outcomes or death with clear protection against major adverse cardiovascular events, heart failure, vascular death and total mortality. In addition, SGLT2 inhibitor treatment was linked to similar relative risks in women and men for the safety results of amputation, fracture, genital infection and urinary tract infection.